Showing results (451-460 of 530) with videos related to

Sort By:
Pageof 53
Thorax|May 2, 2020
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load AssayWilber Sabiiti, Khalide Azam, Eoghan Charles William Farmer, et al.
Trials|August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosisLinda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Nature Communications|October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosisVincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
American Journal of Respiratory and Critical Care Medicine|February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical TrialsEkaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
The New England Journal of Medicine|May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Pageof 53